Cargando…
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
BACKGROUND: PAM4, an antibody that has high specificity for pancreatic ductal adenocarcinoma (PDAC), compared to normal pancreas, benign lesions of the pancreas, and cancers originating from other tissues, is being investigated as a biomarker for early detection, as well as antibody-targeted imaging...
Autores principales: | Gold, David V, Newsome, Guy, Liu, Donglin, Goldenberg, David M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015478/ https://www.ncbi.nlm.nih.gov/pubmed/24257318 http://dx.doi.org/10.1186/1476-4598-12-143 |
Ejemplares similares
-
Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer
por: Liu, Donglin, et al.
Publicado: (2015) -
Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma
por: Manne, Ashish, et al.
Publicado: (2021) -
Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas
por: Do, Sung-Im, et al.
Publicado: (2013) -
Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma
por: Manne, Ashish, et al.
Publicado: (2023) -
Immunohistochemical detection of MUC5AC and MUC5B mucins in ferrets
por: Meyerholz, David K., et al.
Publicado: (2023)